Senti Biosciences Holdings, Inc. (SNTI)
0.3905
0.00 (0.00%)
USD |
NASDAQ |
Aug 26, 15:59
Senti Biosciences Holdings Enterprise Value : 25.94M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 25.94M |
| August 24, 2026 | 25.54M |
| August 21, 2026 | 25.87M |
| August 20, 2026 | 27.34M |
| August 19, 2026 | 28.18M |
| August 18, 2026 | 27.16M |
| August 17, 2026 | 27.16M |
| August 14, 2026 | 27.75M |
| August 13, 2026 | 25.72M |
| August 12, 2026 | 25.45M |
| August 11, 2026 | 24.89M |
| August 10, 2026 | 24.63M |
| August 07, 2026 | 24.78M |
| August 06, 2026 | 24.94M |
| August 05, 2026 | 25.38M |
| August 04, 2026 | 25.75M |
| August 03, 2026 | 25.29M |
| July 31, 2026 | 24.37M |
| July 30, 2026 | 24.99M |
| July 29, 2026 | 24.57M |
| July 28, 2026 | 25.65M |
| July 27, 2026 | 25.40M |
| July 24, 2026 | 26.34M |
| July 23, 2026 | 27.05M |
| July 22, 2026 | 27.48M |
| Date | Value |
|---|---|
| July 21, 2026 | 28.10M |
| July 20, 2026 | 27.27M |
| July 17, 2026 | 27.37M |
| July 16, 2026 | 28.08M |
| July 15, 2026 | 31.93M |
| July 14, 2026 | 43.90M |
| July 13, 2026 | 43.66M |
| July 10, 2026 | 45.84M |
| July 09, 2026 | 44.91M |
| July 08, 2026 | 46.15M |
| July 07, 2026 | 45.22M |
| July 06, 2026 | 47.40M |
| July 02, 2026 | 47.09M |
| July 01, 2026 | 46.78M |
| June 30, 2026 | 48.02M |
| June 29, 2026 | 44.78M |
| June 26, 2026 | 44.15M |
| June 25, 2026 | 43.53M |
| June 24, 2026 | 43.84M |
| June 23, 2026 | 39.00M |
| June 22, 2026 | 40.56M |
| June 18, 2026 | 39.22M |
| June 17, 2026 | 39.82M |
| June 16, 2026 | 39.17M |
| June 15, 2026 | 40.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.190M |
| Brainstorm Cell Therapeutics, Inc. | 12.39M |
| Summit Therapeutics, Inc. | 9.925B |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | 94.82M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.75M |
| Revenue (Quarterly) | 0.017M |
| Total Expenses (Quarterly) | 12.77M |
| EPS Diluted (Quarterly) | -0.4094 |
| Gross Profit Margin (Quarterly) | -3.82K% |
| Profit Margin (Quarterly) | -75.00K% |
| Earnings Yield | -452.0% |
| Normalized Earnings Yield | -460.33 |